Tuesday, 18 Dec 2018

You are here

Excess Mortality in CTD or Systemic Vasculitis Patients

The Norwegian connective tissue disease (CTD) and systemic vasculitis (PSV) registry (NOSVAR) studied patient outcomes over a 15 year period and found overall mortality to be higher in the CTD compared to the PSV group.

A prospective registry of CTD and PSV patients enrolled 2140 patients (1534 with CTD, 606 with PSV) between 1999 and 2015. Cases were matched against 15 sex and age matched controls from the Norwegian National Population Registry. 

After a mean follow-up time of 9 years, 279 patients (13%) died, compared with 9% of 32086 controls (P < 0.001).

Lowest 10 year survival was seen in diffuse cutaneous systemic sclerosis (dcSSc) at 60%; this was followed by  73% in anti-synthetase syndrome (ASS) and 75% in limited cutaneous SSc patients.

In the CTD and primary systemic vasculitis (PSV) patients, the highest standard mortality ratios (SMRs) included:

  • dcSSc SMR = 5.8)
  • ASS SMR = 4.1
  • Takayasu arteritis SMR = 2.5
  • ANCA-associated vasculitis SMR = 1.5)

Overall, the major causes of death were cardiovascular disease (CTD 27%, PSV 28%), neoplasms (CTD 25%, PSV 27%), chronic respiratory disease (CTD 20%, PSV10%) and infections (CTD 9%, PSV 16%).

These data call for strategies to address the excess mortality seen among patients with CTD and PSV. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Genetic Diagnosis for Previously Undiagnosed Disorders

The NEJM has reported the NIH's Undiagnosed Diseases Network (UDN) study results of genetically identifying new diseases from prospectively followed persons with undiagnosed disorders. The UDN was formed in 2014 as a network of seven clinical sites, two sequencing cores, a coordinating center, central biorepository, a metabolomics core, and a model organisms screening center. It was established to apply a multidisciplinary model in the evaluation of the most challenging cases and to identify the biologic characteristics of newly discovered diseases.

SLE and Risk of Malignancy

The risk for cancer in systemic lupus erythematosus (SLE) patients has been inconsistently studied.  A new metanalysis shows that SLE has an increased risk for 16 specific cancers and decreased risk for prostate cancer and cutaneous melanoma. 

The Benefits of a Lupus Clinic

A comparative cohort study assessing the quality of care in patients with systemic lupus erythematosus (SLE) suggests that a dedicated lupus clinic has better quality measure performance compared to lupus management in a general rheumatology clinic.

A study from Rush University enrolled 150 consecutive SLE patients - with 73 followed in the general rheumatology clinic and 77 followed in a dedicated lupus clinic. 

Diagnosing Early Lupus from Mimics

A multicenter study of early systemic lupus erythematosus (SLE) patients examined manifestations at disease onset and found that certain clinical features can help to distinguish early SLE from other SLE‐mimicking conditions. 

High CV Risk in Lupus

Patients with systemic lupus erythematosus (SLE) remain at risk for accelerated atherosclerosis, and important questions have yet to be answered, British investigators reported.